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Abstract
Background: The chromodomain, helicase DNA-binding protein 5 (CHD5) is a potential tumor suppressor gene
located on chromosome 1p36, a region recurrently deleted in high risk neuroblastoma (NB). Previous data have
shown that CHD5 mRNA is present in normal neural tissues and in low risk NB, nevertheless, the distribution of
CHD5 protein has not been explored. The aim of this study was to investigate CHD5 protein expression as an
immunohistochemical marker of outcome in NB. With this purpose, CHD5 protein expression was analyzed in
normal neural tissues and neuroblastic tumors (NTs). CHD5 gene and protein expression was reexamined after
induction chemotherapy in a subset of high risk tumors to identify potential changes reflecting tumor response.
Results: We provide evidence that CHD5 is a neuron-specific protein, absent in glial cells, with diverse expression
amongst neuron types. Within NTs, CHD5 immunoreactivity was found restricted to differentiating neuroblasts and
ganglion-like cells, and absent in undifferentiated neuroblasts and stromal Schwann cells. Correlation between
protein and mRNA levels was found, suggesting transcriptional regulation of CHD5. An immunohistochemical
analysis of 90 primary NTs highlighted a strong association of CHD5 expression with favorable prognostic variables
(age at diagnosis <12 months, low clinical stage, and favorable histology; P < 0.001 for all), overall survival (OS)
(P < 0.001) and event-free survival (EFS) (P < 0.001). Multivariate analysis showed that CHD5 prognostic value is
independent of other clinical and biologically relevant parameters, and could therefore represent a marker of
outcome in NB that can be tested by conventional immunohistochemistry. The prognostic value of CHD5 was
confirmed in an independent, blinded set of 32 NB tumors (P < 0.001).
Reactivation of CHD5 expression after induction chemotherapy was observed mainly in those high risk tumors with
induced tumor cell differentiation features. Remarkably, these NB tumors showed good clinical response and pro-
longed patient survival.
Conclusions: The neuron-specific protein CHD5 may represent a marker of outcome in NB that can be tested by
conventional immunohistochemistry. Re-establishment of CHD5 expression induced by chemotherapy could be a
surrogate marker of treatment response.
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Neuroblastic tumors (NTs) are embryonal cancers aris-
ing from neural crest derived sympathetic nervous sys-
tem precursors. These neoplasms are the most
common extracranial solid tumors in childhood and
account for approximately 15% of all pediatric oncol-
ogy deaths [1].
Neuroblastoma (NB), the most undifferentiated form
of NTs, embodies a heterogeneous spectrum of diseases
whereby patients with similar clinicopathological fea-
tures exhibit radically different outcomes ranging from
spontaneous regression to inexorable progression. Since
treatment strategies vary from a “watchful waiting”
approach to multimodal intensive regimens, precise risk
assessment is critical for therapeutic decisions. Various
combinations of prognostic markers have been used
with success for risk group distinction, including clini-
cal, histologic and genetic factors, yet there remain cases
where established indicators of aggressiveness have
demonstrated limited clinical utility. Additional para-
meters are therefore needed for a more precise identifi-
cation and therapeutic targeting of high risk NB
patients.
There is an apparent link between NB aggressiveness
and specific genetic aberrations. One of the most recur-
rent genetic alterations described is the deletion of the
short arm of chromosome 1 found in approximately
35% of NB [2]. The high incidence of chromosome 1p
deletion in human cancer [2], with 1p36 deletion being
the most common alteration [3], has led to an extensive
search for 1p36 tumor suppressor genes. Recent findings
have identified the CHD5 gene as a candidate tumor
suppressor [4,5] mapping to the smallest region of dele-
tion (SRD) described in NB, 1p36.31 [6]. Evidence sup-
porting CHD5 as a tumor suppressor is the recently
reported strong promoter methylation and transcrip-
tional silencing of the remaining allele in 1p deleted NB
cell lines [5]. Nevertheless, low or absent CHD5 expres-
sion levels have been found in NB cell lines lacking pro-
moter methylation [7], 1p deletion, or inactivating
mutations [6], suggesting other mechanisms by which
CHD5 expression may be inhibited.
CHD5 is one of the nine members of the chromodo-
main helicase DNA-binding (CHD) family of enzymes
that belong to the ATP-dependent chromatin remodel-
ing protein SNF2 superfamily [8]. CHD protein struc-
ture is characterized by two N-terminal chromodomains
and a SNF2-like ATPase central domain that defines the
chromodomain remodeling proteins [9,10]. The mem-
bers of this evolutionarily conserved class of proteins
play a critical role in organizing the chromatin structure
and accordingly, in chromatin based transcriptional reg-
ulation of genes.
The aberrant expression of some of the CHD genes
has been associated with human disease processes like
CHARGE syndrome, Hodgkin’s lymphoma or dermato-
myositis [8]. CHD5 mRNA expression, restricted to neu-
ronal-derived tissues and the adrenal gland in normal
tissues [10], is basically absent in NB primary tumors
with high risk features, MYCN amplification, advanced
stage and 1p monosomy [5].
The distribution of CHD5 protein in NTs and normal
neural tissues has not been explored. Like neural tissue,
NTs consist of two main cell populations, neuroblastic
cells and Schwann-like cells. The malignant potential of
these tumors is inherently dependent on the proportion
of immature neuroblastic cells and the abundance of
Schwann cell stromal component, Schwannian stroma-
poor undifferentiated NB being the most malignant.
CHD5 expression remains to be investigated in these
two cell populations. In the present study, we analyzed
by immunohistochemistry normal neural derived tissues
and NTs to visualize CHD5 protein distribution within
the different cell populations. Because impaired CHD5
expression is associated with high risk NB tumors, we
asked whether CHD5 protein expression might serve as
an immunohistochemical marker of outcome in NB. It
is known that gene expression pattern can change with
treatment, for this reason, CHD5 gene and protein
expression was re-examined after induction treatment in
a set of paired cases.
Material and Methods
Patients and tumor samples
A total of 90 primary tumor specimens (63 NB, 14
ganglioneuroblastomas (GNB) and 13 ganglioneuromas
(GN)) (Additional file 1) were obtained at diagnosis
from two institutions (Hospital Sant Joan de Déu
(HSJD) of Barcelona and Memorial Sloan-Kettering
Cancer Center (MSKCC) of New York) together with 12
high risk NB cases with available paired diagnostic and
post-chemotherapy tumor specimens. An independent
set of 32 NB tumors was obtained from Children’s Hos-
pital of Boston and Dana-Farber Cancer Institute (CHB/
DFCI) for data validation analysis. Non-tumor samples
(fetal brain, adult cerebral cortex, adult cerebellum,
adrenal gland, bone marrow, spinal cord and sympa-
thetic ganglion) were also included in this study.
NB risk assessment was defined by the International
Neuroblastoma Staging System (INSS) [11]. NB stages 1,
2, 3 (MYCN non-amplified) and 4s were uniformly treated
without use of cytotoxic therapy, when possible. Stage 4
and stage 3 MYCN amplified NB patients were treated
according to N5, N6 or N7 protocols. This study was
approved by the Institutional Review Boards and informed
consent was obtained before collection of samples.
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tumors with >70% viable tumor cell content were
included in the study.
Seven NB cell lines (LA-N-1, SKNSH-SY5Y, SK-N-Be
(2)C, SKNSH-EP1, SK-N-JD, SK-N-LP and SK-N-AS)
were used in this study. NB cell lines were cultured in
RPMI-1640 supplemented with 10% fetal bovine serum
(FBS), 2 mM L-glutamine and penicillin (100 U/ml) and
streptomycin (100 μg/ml) (GIBCO, Invitrogen, US) at
37°C in 5% CO2 atmosphere.
In vivo study
NB cell lines SK-N-JD, SK-N-LP and SK-N-AS were
harvested and resuspended in phosphate buffered saline
(PBS) solution and BD Matrigel Basement Membrane
Matrix (BD Biosciences, US). One hundred microliters
of cell suspension containing 8 × 10
6 cells were subcuta-
neously inoculated into the right flank of six-week old
CD-1 Nude (nu/nu) mice (Charles River Laboratories,
Europe). Mice were killed when NB cell lines developed
tumors that exceeded 1.5 cm
3. Tumors were removed
surgically, fixed in 10% formalin and embedded in paraf-
fin for histological examination.
Immunohistochemistry
Immunohistochemical (IHC) analysis was performed on
formalin-fixed, paraffin-embedded (FFPE) tissues using
rabbit-polyclonal anti-CHD5 antibody (Strategic Diag-
nostics, DE) at a 1:1000 dilution for 1 hour; mouse-poly-
clonal anti-Neurofilament protein, 68kD (NF68)
antibody (Zymed, US) 1:300 dilution, 1 hour and
mouse-polyclonal anti-Glial fibrillary acidic protein
(GFAP) antibody (Novocastra, UK) 1:200 dilution, 2
min. Two different anti-CHD5 antibody batches
(T00251-A1 and T00251-A02, Strategic Diagnostics,
DE) have been tested in this study. Normal human
brain was used as positive control.
Slides were examined by a pathologist (M.S.) using an
Olympus BX41 light microscopy to assess staining and
score both percentage of positive cells and staining
intensity (0, negative; 1, weak; 2, strong and 3, very
intense staining). Integer values were assigned to the
proportion of positive cells (<25% = 1; 25-75 = 2; >75%
= 3). Intensity and positive cell values were multiplied
to provide a single score for each case.
Double fluorescent immunostaining: Paraformaldehyde
(4%, pH 7.4) fixed cryosections, blocked with bovine
serum albumin (BSA) 1% for 1 hour, were incubated
overnight at 4°C with a rabbit-polyclonal anti-CHD5
antibody (H-185) (Santa Cruz, US) at 1:1000 dilution,
followed by anti-rabbit IgG Cy3-conjugated antibody,
(Sigma, US) 1:400 dilution for 45 min. Sections were
subsequently incubated with anti-NF68 antibody (1:300
dilution) 1 hour or anti-GFAP antibody (1:200 dilution)
2 min, and stained with anti-mouse IgG FITC-conju-
gated antibody (Sigma, US) 1:700 dilution, 45 min.
Nuclei were counterstained with 4’6-diamino-2-pheny-
lindole (DAPI) (Sigma, US), 1:5000 dilution, 5 min.
Paraformaldehyde fixed bone marrow aggregates were
incubated with anti-GD2 antibody (BD Biosciences, US)
1:800 dilution 1 hour and stained with anti-mouse IgG-
FITC antibody at 1:700 dilution, 45 min, or with anti-
CHD5 antibody as described above.
Immunoreactivity was evaluated with a Leica epifluor-
escence DM5000B microscope (Leica Microsystems,
US).
Western blot analysis
Proteins were extracted from cell lines and homogenized
tissue in lysis buffer (20 mM Tris pH 8.8, 80 mM NaCl,
1% NP-40 and protease inhibitors). Protein concentra-
tions were quantified using the Bradford method (Bio-
Rad laboratories, US) and 30 μg of protein were resolved
on an 8% SDS-PAGE. Membranes were incubated with
polyclonal anti-CHD5 antibody (1:2000; Strategic Diag-
nostics, DE) and monoclonal anti b-actin antibody
(1:5000; Sigma, US) and detected with donkey anti-rab-
bit IgG HRP-conjugated antibody (1:2500; Affinity BioR-
eagents, Inc., US) and goat anti-mouse IgG HRP-
conjugated antibody (1:5000; Sigma, US) respectively.
Antibody conjugates were visualized by enhanced che-
miluminescence (ECL, Amersham Life Science, US).
RNA isolation and cDNA synthesis
Total RNA was isolated from snap frozen samples and
cell lines using Tri Reagent (Sigma, US), following man-
ufacturers’ protocols. cDNA was synthesized from 1 μg
total RNA using random primers and M-MLV reverse
transcriptase (Promega, US) as previously described [12].
Quantitative Real-time Polymerase Chain Reaction (qRT-
PCR)
Quantification of transcript levels, using the ΔΔCT rela-
tive quantification method, were performed on an ABI
Prism 7000 Sequence Detection System with TaqMan®
Assay-on-Demand Gene Expression products (Applied
Biosystems, US), as previously reported [12].
Statistical analysis
Comparisons between immunohistochemical results
were performed by means of the log-rank test. qRT-
PCR transcript levels were normalized by z-score trans-
formation to enable a correlation analysis with the
immunostaining score values. Correspondence between
immunoreactivity and mRNA expression levels within
the same samples was examined using the Spearman’s
correlation coefficient analysis. Statistical analyses for
qualitative variables were performed by means of the
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tative or ordinal variables. Overall survival (OS) and
event-free survival (EFS) probabilities were estimated
using the Kaplan-Meier method. Multivariate Cox
regression models were used to examine the prognostic
significance of CHD5, INSS stage, age at diagnosis,
MYCN status and 1p LOH. Each variable consisted of
two groups: “INSS stage” consisted of: (1) ST1, 2, 3 and
4s, and (2) ST4; “age” (at diagnosis): (1) ≤ 12 months (2)
>1 2m o n t h s ;“MYCN“:( 1 )MYCN non-amplified (2)
MYCN amplified; “LOH": (1) no LOH (2) LOH. Predic-
tive Positive and Negative Values (PPV and NPV) were
used for a descriptive comparison between CHD5
expression and MYCN a n d1 pL O H .A l lr e p o r t e d
P-values are two-sided. P-values ≤0.05 were considered
statistically significant. Statistical analysis was performed
with SPSS 15.0 package (SPSS, Chicago, IL).
Results
CHD5 protein expression in normal neural tissues is
restricted to neuronal cells
In normal human neural tissue sections (brain cortex,
cerebellum, spinal cord and sympathetic ganglion),
CHD5 immunoreactivity was found restricted to neu-
rons, whereas glial cells were consistently negative (Fig-
ure 1A, C, D and 1E). CHD5 expression pattern was
confirmed by immunostaining with neuronal (NF68)
and glial (GFAP) cell markers. Frozen brain sections
analyzed by double immunofluorescence showed co-
localization of CHD5 and NF68 in neurons. No CHD5
protein expression was observed in GFAP positive glial
cells (Figure 1G and 1H).
Intensity and intracellular localization of CHD5 stain-
ing in the cerebral cortex varied among neuron types
but did not exhibit a layer-related expression (Figure
1A). Nuclear labeling was intense in morphologically
small neurons with scarce cytoplasm present in all corti-
cal layers identified by size and location as interneurons.
Larger neurons with triangular shaped soma, including
pyramidal neurons present in cortical layers III, IV and
V, exhibited essentially negative or lower intensity of
nuclear staining and diffuse cytoplasm reactivity (Figure
1A). In the cerebellum, Purkinje cells and deep nuclei
neurons exhibited intense nuclear and diffuse cytoplasm
staining. Cerebellar granular layer neurons lacked
immunoreactivity (Figure 1C).
Spinal cord specimens were characterized by intense
positive neuron processes, predominantly located in the
external white matter, and large motoneuron cell bodies
with positive cytoplasm and mostly negative nuclear
staining (Figure 1D). All glial cells, including the epen-
dymal cells lining the central canal of the spinal cord,
were negative for CHD5 expression (Figure 1D*). In the
sympathetic ganglia, neuron cell bodies showed intense
nuclear and diffuse cytoplasm reactivity, while the stro-
mal cell component was found negative for CHD5 (Fig-
ure 1E).
Adrenal gland specimens exhibited weak CHD5
expression, mainly in the nucleus of the medullary cells.
Neuroblastic aggregates found in fetal adrenal glands
(19-20 weeks) were essentially negative, although few
intermixed positive cells were identified in larger neuro-
blastic islets (Figure 1F).
CHD5 expression was evaluated in brain cortex speci-
mens and in NB cell lines by immunoblot analysis.
CHD5 protein (250-260 kDa) was detected only in brain
cortex specimens, both in the total protein extract and
in the nuclear fraction. No CHD5 protein was detected
in the cytoplasmic fraction of all the analyzed specimens
or in NB cell lines (Figure 1B).
These results identify CHD5 as a neuron-specific pro-
tein, absent in glial cells, with a diverse expression pat-
tern amongst neuron types. Human immature
neuroblastic aggregates in the developing adrenal gland
are mostly negative for CHD5.
CHD5 protein is expressed in the neuroblastic component
of low clinical risk NTs
CHD5 immuno-localization was investigated in a total
of 90 primary NTs (63 NB including 24 stage 4, 8 stage
4 sa n d3 1l o c o - r e g i o n a lN B ;1 4G N Ba n d1 3G N )
(Table 1).
Stage 4 NB cases, all histologically undifferentiated
high risk NB, appeared predominantly (20/24) negative
or with <25% neuroblastic cells with faint CHD5 nuclear
reactivity (Figure 2A and 2E; Table 1, Additional file 1).
Only 3/24 undifferentiated NB tumors exhibited weak
nuclear reactivity in 25-75% of cells, and one had
intense nuclear staining in >75% of tumor cells. In con-
trast, stage 4s NB, histologically undifferentiated low
risk tumors, showed consistently (8/8) very intense
CHD5 nuclear positivity in >75%, generally >90% of the
neuroblasts (Figure 2F, Table 1, Additional file 1). This
clinically low risk NB is, nevertheless, a highly prolifera-
tive metastatic tumor. Thus, for 2 stage 4s NB tumors,
CHD5 expression was also evaluated in the liver and
bone marrow metastases. Intense CHD5 immunopositiv-
ity, equivalent to the primary tumor, was observed in
>75% neuroblasts disseminated in the liver. Intriguingly,
bone marrow neuroblastic aggregates, identified using
an antibody against the ganglioside GD2 ubiquitously
expressed in NB (data not shown), lacked CHD5 immu-
noreactivity (Figure 2H), similar to stage 4 bone marrow
smears (Figure 2G).
Loco-regional tumors (stage 1, 2, and 3) displayed
more heterogeneous expression patterns (Figure 2B and
2C; Additional file 1), with staining values being highest
in differentiating NB, where intense nuclear staining was
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Page 4 of 14Figure 1 CHD5 protein expression in normal human neural tissues. CHD5 immunostaining in (A) normal neural tissue, cerebral cortex
(100x), box: pyramidal and interneuron CHD5 staining (400x); (B) expression of CHD5 protein detected by immunoblotting in (1) brain cortex
total protein, (2) brain cortex nuclear protein fraction, (3) brain cortex cytoplasmatic fraction, (4) LA-N-1 NB cell line total protein and (5) LA-N-1
nuclear fraction; CHD5 predicted molecular weight of 250-260 kDa is based on the amino acid composition (ref. 5); all analyzed samples
displayed a 150-160 kDa size band, not yet characterized; (C) Cerebellum (100x), box: Purkinje cell CHD5 staining (400x); (D) Spinal cord (100x),
box: Motoneuron CHD5 staining (400x), box*: ependymal cells lining canal spinal cord (100x); (E) Sympathetic ganglia (100x), box: Ganglion cell
CHD5 staining (400x); (F) immature neuroblast aggregates within fetal adrenal gland (200x), (arrow) CHD5 immunopositive neuroblasts; (G-H)
double fluorescent immunostaining, (G, arrow) NF68
+/CHD5
+ neuron; (H, arrow) GFAP
+/CHD5
- astrocyte, (H, arrow head) GFAP
-/CHD5
+ neuron.
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Page 5 of 14observed in >75% of neuroblastic cells (13/32) (Figure
2B; Additional file 1), and lowest in stage 3 MYCN
amplified NB composed mainly of undifferentiated neu-
roblasts with undetectable immunoreactivity, similar to
stage 4 NB cases (Figure 2C, Table 1, Additional file 1).
GNB (14/14) and GN (13/13) tumors exhibited gang-
lion-like cells with intense nuclear and diffuse cytoplasm
staining. Absence of nuclear staining and feeble cyto-
plasmic reactivity was observed in Schwann-like cells
(Figure 2D; Additional file 1). The undifferentiated neu-
roblastic component of GNB lacked CHD5 staining
(Table 1, Additional file 1).
The described immunohistochemical assays were per-
formed using two different batches of the anti-CHD5
antibody (T00251-A1 and T00251-A02). Both batches
performed consistently across many repeats, further sup-
porting the validity of our results (Additional file 2A).
The specificity of the anti-CHD5 antibody was further
validated on mouse xenografts of human NB cell lines
(SK-N-JD, SK-N-LP and SK-N-AS). All the xenografts
were found to be negative for CHD5 staining (Addi-
tional file 2B).
Altogether, CHD5 protein was expressed in the
nucleus of neuroblastic cells of clinical low risk NTs. In
stage 4s NB, CHD5 negative neuroblast bone marrow
metastasis imply the existence of intratumoral clones
with CHD5 differential expression in an otherwise histo-
logically homogeneous tumor subtype.
CHD5 transcript levels are associated with protein
expression
CHD5 protein expression was contrasted with gene
transcript levels. Quantification of CHD5 mRNA in
non-tumoral frozen tissue samples using qRT-PCR iden-
tified high expression in fetal brain and adult cerebral
cortex, as reported previously [10]. Normal bone mar-
row specimens lacked CHD5 expression.
CHD5 mRNA levels were analyzed for 84 primary
NTs obtained at diagnosis (23 stage 4; 7 stage 4s; 34
l o c o - r e g i o n a lN B ;9G N Ba n d1 1G N ) ;5 5o ft h e s e
tumors were also analyzed by immunohistochemistry.
High risk undifferentiated NB tumors, stage 4 and
stage 3 MYCN-amplified NB displayed significantly
lower mRNA expression levels than stage 1, 2, 3 (P <
0.001) and stage 4s NB (P = 0.001) (Additional file 3).
The highest mean expression values, similar to normal
fetal brain, were found for stage 4s NB. GN specimens
displayed consistently low CHD5 transcript levels,
whereas, GNB tumors were characterized by highly vari-
able expression attributable to the presence of CHD5
negative component, Schwann-like stroma and undiffer-
entiated neuroblasts, besides the positive ganglion-like
cells that compose these tumors.
Correlation between CHD5 immunoreactivity and
mRNA expression levels within the same samples was
examined in a set of 34 consecutive NB tumors. Immu-
nohistochemical and qRT-PCR analyses were carried
out on the same portion of the tumor specimen, with
similar cell composition and a high tumor cell content
(>70% as recommended for PCR studies). CHD5 nuclear
immunoreactivity was assigned a staining score (Addi-
tional file 1) and gene expression values were z-score
transformed. A significant correlation was observed
between mRNA and protein levels (Spearman’sr h o=
0.774; P < 0.001), low CHD5 protein scores were consis-
tently associated with low mRNA levels (negative z-
score values), and high IHC scores with high mRNA
expression (positive z-score values) (Additional file 4).
Interestingly, very intense nuclear staining displayed by
low risk tumors, mostly stage 4s and infant stage 1 NB,
was not associated with the highest transcript levels
(Additional file 4, cases # 1-6, 30, 31 and 33).
These results reveal a correspondence between CHD5
protein and mRNA expression, suggesting a potential
regulation of CHD5 expression at the transcriptional
level.
CHD5 protein expression is associated with patient
outcome in NB
CHD5 nuclear immunoreactivity was assigned a staining
score (Additional file 1) and compared to clinical and
biological variables currently used for NB risk classifica-
tion. High CHD5 staining values were found to be sig-
nificantly associated with INSS stages 1, 2, 3 (MYCN
non-amplified) and 4s NB (n = 63), age at diagnosis <12
m (n = 63) and favorable tumor histology (n = 63); P <
0.001 for all the tested variables.
To assess whether CHD5 expression was associated
with patient outcome, immunoreactivity scores were
compared to overall survival (OS) and event-free survi-
val (EFS) for all 63 NB tumors. The median score value
Table 1 CHD5 inmunostaining in Neuroblastic tumors
Percentage of CHD5 immunopositive neuroblastic
cells
n <25% 25-75% >75%
St 1,2,3 31 10/31 (32.2%) 9/31 (29%) 12/31 (38.7%)
St 4 24 19/24 (79.1%) 4/24 (16.6%) 1/24 (4.1%)
St 4s 8 –– 8/8 (100%)
GNB 14 14/14* (100%) – 14/14** (100%)
GN 13 –– 13/13 (100%)
Total 90 29 13 48
Percentage of CHD5 positive (nuclear staining) tumor cells within each
neuroblastic tumor group evaluated using predetermined cutoff values (<25%;
25-75%; >75%). Detailed data regarding percentage of positive tumor cells
and staining intensity are reported in Additional file 1. For GNB tumors, the
undifferentiated neuroblastic (*) and the ganglionar (**) cell populations were
scored separately. GNB = ganglioneuroblastoma, GN = Ganglioneuroma.
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Page 6 of 14Figure 2 CHD5 protein expression in neuroblastic tumors. CHD5 immunostaining in (A) stage 4 undifferentiated NB (400x); (B) loco-regional
differentiating NB (400x); (C) stage 3, MYCN amplified, undifferentiated NB (400x); (D) Ganglioneuroblastoma (100x); (E) stage 4 (200x) and (F)
stage 4s primary tumor (200x) with bone marrow neuroblast aggregates (G-H), respectively (400x).
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Page 7 of 14was used as a cut-off to define high (>2) and low (≤2)
CHD5 expressing NB tumors. High CHD5 expression
was found to be significantly associated with a better OS
(log-rank test P < 0.001) and EFS (log-rank test P <
0.001) (Figure 3A and 3B). Furthermore, using this cut-
off, Cox multivariate analysis showed that expression of
CHD5 protein predicted OS and EFS independently of
INSS stage, patient age, amplification of MYCN and 1p
LOH (Table 2; Additional file 5). Specifically, CHD5
IHC was the only variable that remained statistically sig-
nificantly associated with event-free survival in both the
univariate and multivariate analyses (Table 2; Additional
file 5). CHD5 IHC remained statistically significantly
associated with overall survival, except when 1p LOH
was included in the multivariate analysis, owing to the
strong association of CHD5 expression with
Figure 3 Expression of CHD5 protein is prognostic for neuroblastoma patients. Kaplan-Meier analysis documenting increased overall
survival and event-free survival of neuroblastoma patients with tumors that have high CHD5 immunoreactivity versus patients with tumors that
have low CHD5 expression, (A) overall survival (P < 0.001) and (B) event-free survival (P < 0.001). The analysis was performed with all 63 NB
tumors, including all stages (stage 1, 2, 3, 4s and 4). Independent validation performed on 32 primary NB samples (C) overall survival (P = 0.001)
and (D) event-free survival (P < 0.0001). DOD = dead of disease.
Garcia et al. Molecular Cancer 2010, 9:277
http://www.molecular-cancer.com/content/9/1/277
Page 8 of 14chromosome 1p status (Table 2; Additional file 5). The
Predictive Value of CHD5 staining was evaluated and
compared to MYCN a n d1 pL O H( T a b l e3 ) .C H D 5
expression showed the highest Negative Predictive
Value (NPV) for overall survival status (96.4%) and
event free survival (85.7%). MYCN status and 1p LOH
showed a NPV of 81.6% and 78.9%, respectively, for
the overall survival status, and of 65.3% and 63.2%,
respectively, for the event free survival. The Positive
Predictive Value (PPV) of CHD5 expression (overall
survival status: 54.3%; event free survival: 71.4%), i.e.
proportion of events or deaths in patients with low
CHD5 expressing tumors, was intermediate between
MYCN (66.7% and 77.8%, respectively) and 1p LOH
(46.7% and 60%, respectively) values. CHD5 IHC
showed high sensitivity and accuracy rate for the pre-
diction of OS (95% and 73%, respectively) and EFS
(86.20% and 77.80%) (Table 4).
The prognostic value of CHD5 expression was validated
on an independent, blinded set of 32 FFPE primary NB
tumors of patients diagnosed and treated at the Chil-
dren’s Hospital of Boston (n = 21) and HSJD of
Table 2 Cox regression analysis
Overall Survival
Variable HR and 95%CI p-value Variable HR and 95%CI p-value Interaction p-value
&
CHD5 IHC 21.28 (2.84-159.39) 0.003
CHD5 IHC 18.67 (2.27-153.88) 0.007 0.951
INSS 4.15 (1.63-10.58) 0.003 INSS 1.24 (0.46-3.29) 0.673
CHD5 IHC 15.17 (1.89-121.73) 0.011 0.931
Age (>12 m) 5.56 (1.61-19.19) 0.007 Age (>12 m) 2.14 (0.59-7.75) 0.249
CHD5 IHC 12.29 (1.56-96.49) 0.017 0.952
MYCN (*) 14.27 (4.28-47.58) < 0.001 MYCN(*) 8.08 (2.43-26.93) 0.001
CHD5 IHC 14.33 (1.84-111.48) 0.011 0.946
LOH(**) 2.88 (1.04-7.96) 0.042 LOH(**) 1.75 (0.63-4.89) 0.287
Event Free Survival
Variable HR and 95%CI p-value Variable HR and 95%CI p-value Interaction p-value
&
CHD5 IHC 8.14 (2.82-23.5) <0.001
CHD5 IHC 7.01 (2.09 to 23.51) 0.002 0.939
INSS 3.7 (1.73-7.88) 0.001 INSS 1.26 (0.53 to 2.97) 0.605
CHD5 IHC 7.04 (2.24 to 22.09) 0.001 0.638
Age (>12 m) 3.13 (1.33-7.39) 0.009 Age (>12 m) 1.36 (0.54 to 3.44) 0.515
CHD5 IHC 5.97 (1.98 to 17.98) 0.001 0.933
MYCN (*) 4.58 (1.84-11.42) 0.001 MYCN 2.72 (1.07 to 6.88) 0.035
CHD5 IHC 6.02 (1.98 to 18.34) 0.002 0.492
LOH(**) 2.12 (0.92-4.91) 0.079 LOH 1.24 (0.52 to 2.95) 0.622
Cox regression analysis of the NB cohort using CHD5 protein expression and clinical and biologically relevant variables (INSS stage, patient age at diagnosis,
MYCN amplification status and chromosome 1p LOH). Expression of CHD5 was statistically significantly associated with overall survival and event-free survival in
both the univariate and multivariate analyses. All NB patients (n = 63) where included in the study except for the studies with MYCN amplification (n = 58) and
1p LOH (n = 53), due to the undetermined status in some patients. IHC = Immunohistochemical analysis; INSS = International Neuroblastoma Staging System; HR
= hazard ratio; CI = confidence interval. P-values are two sided. (
&) Interaction P-values obtained from Cox regression model: IHC + Co-factor+IHC*Co-factor. (*)
data available for 58 patients; (**) data available for 53 patients.
Table 3 Analysis of the Predictive Value was performed for a descriptive comparison between CHD5 expression and
MYCN and 1p LOH
Overall Survival Event Free Survival
Alive Dead PPV NPV No event Event PPV NPV
CHD5 IHC High 27 (62.8%) 1 (5%) 54.30% 96.40% 24 (70.6%) 4 (13.8%) 71.40% 85.70%
Low 16 (37.2%) 19 (95%) 10 (29.4%) 25 (86.2%)
MYCN Non amplified 40 (93%) 9 (60%) 66.70% 81.60% 32 (94.1%) 17 (70.8%) 77.80% 65.30%
Amplified 3 (7%) 6 (40%) 2 (5.9%) 7 (29.2%)
1p LOH No 30 (78.9%) 8 (53.3%) 46.70% 78.90% 24 (80%) 14 (60.9%) 60% 63.20%
LOH 8 (21.1%) 7 (46.7%) 6 (20%) 9 (39.1%)
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Page 9 of 14Barcelona (n = 11). Kaplan-Meier analysis and a log-
rank test showed a statistically significant difference in
OS (log-rank test P = 0.001) and EFS (log-rank test P <
0.0001) between patients with high and low CHD5
expression scores (Figure 3C and 3D). Tumors with
high IHC scores were associated with longer survival
(mean 73 months) in comparison with low expressing
tumors (mean 46 months).
These results suggest that CHD5 protein expression is
a potential prognostic marker of outcome in NB
patients.
CHD5 expression reactivation is associated with tumor
response to induction therapy
Tumor histology and gene expression can change with
treatment as a result of important changes in cellular
processes. We investigated the effects of induction che-
motherapy (3 cycles) on CHD5 expression in 12 high
risk NB cases with available paired diagnostic and post-
chemotherapy tumor specimens for qRT-PCR and
immunohistochemical analyses. At diagnosis all these
tumors (2 locoregional and 10 stage 4 NB) displayed
low CHD5 mRNA expression and negative immunos-
taining. Following induction chemotherapy, a significant
increase of CHD5 transcript and CHD5 positive nuclear
staining was detected in 6/12 specimens, together with
therapy-induced morphological changes (increased cyto-
plasm and ganglion-like cell morphology) (Figure 4A
and 4C; cases #1-6). All these patients achieved an initial
complete or very good response to cytotoxic therapy
(chemo- and radiation therapy). At the time of analysis,
5/6 patients were alive with a mean follow-up of 35.62
months (Figure 4B). One case, stage 4 MYCN amplified,
progressed after a good initial response to chemotherapy
and died of refractory bone marrow disease (Figure 4C;
case #6). Bone marrow aspirate smears of this patient
exhibited widespread tumor dissemination with CHD5
negative neuroblast aggregates (data not shown).
In contrast, low gene and protein expression levels
persisted in the 6 remaining post-therapy specimens (6
stage 4 NB; 3/6 MYCN amplified and 1p36 deleted
tumors) (Figure 4A and 4C; cases #7-12). Therapy
induced neuroblastic differentiation was observed in
only one of these samples (case #7), a stage 4 NB with
aberrant morphological changes. All 6 patients died of
rapid disease progression with no signs of clinical
response; with a mean survival of 12.73 months (Figure
4B).
These observations suggest a relationship between
CHD5 expression reactivation and response to induction
therapy and subsequent patient outcome.
Discussion
Gene expression of CHD5, an ATP-dependent chroma-
tin remodeling enzyme, has been reported to be
restricted essentially to the nervous system [8,10]. We
describe for the first time that CHD5 is a neuron speci-
fic protein in normal neural tissue, with variable immu-
nostaining intensity and intracellular localization among
the neuron types of the cerebral cortex. Recent evi-
dences suggest that the diverse neuron cell classes
derive from distinct embryonal germinal zones and are
characterized by specific cell signaling systems that reg-
ulate neural stem cells throughout the developing brain
[13-15]. Thus, neuronal cells adopt a brain layer fate
determined by their molecular profiles [14]. While we
did not observe a layer specific distribution of CHD5 in
the cerebral cortex, we did note an association of CHD5
expression with neurons with distinct morphological,
physiological and neurochemical features.
In normal neural tissue, glial cells appeared consis-
tently devoid of CHD5 expression. In human glial
tumors, chromosome arm 1p allelic loss is a frequent
genetic abnormality, especially in oligodendrogliomas
(70-85%) and astrocytomas (20-30%) [16]. Recently, low
levels of CHD5 expression have been reported in glio-
mas with 1p deletion, whereas nondeleted tumors dis-
played expression levels comparable to normal brain [4].
Thus, deletion of CHD5 has been proposed as an initiat-
ing event in gliomas [4]. Our findings, however, suggest
that the role of CHD5 as a tumor suppressor in glial
tumors needs further investigation.
NTs are embryonal cancers that are assumed to origi-
nate from primitive sympathetic neuroblast aggregates
located in neural crest derived sympathetic nervous sys-
tem. We observed how primitive neuroblast aggregates
found in fetal adrenal gland specimens generally lack
CHD5 expression. Interestingly, only a few cells were
found with a variable degree of nuclear reactivity in lar-
ger aggregates. To date, the fate of these immature neu-
roblastic aggregates remains unsolved, and spontaneous
involution and cell maturation have been proposed [17].
Table 4 Comparison of sensitivity, specificity and accuracy rate between CHD5 expression, MYCN status and 1p LOH
Overall Survival Event Free Survival
Sens Specif Accurancy Sens Specif Accurancy
CHD5 IHC 95.00% 62.80% 73.00% 86.20% 70.60% 77.80%
MYCN 40.00% 93.00% 79.30% 29.20% 94.10% 67.20%
1p LOH 46.70% 78.90% 69.80% 39.10% 80.00% 62.30%
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Page 10 of 14The immunoreactivity observed in a small proportion of
neuroblasts within these islets could suggest the estab-
lishment of CHD5 expression prior to their disappear-
ance; however, no evident differentiating features were
observed in these immunopositive cells that suggested
the activation of the maturation process.
In NTs, CHD5 is essentially expressed in the nucleus
of differentiating neuroblastic cells and ganglion cells,
and absent in the Schwannian stromal component.
However, the most intense immunoreactivity was
observed in stage 4s NB, a rare subgroup of histologi-
cally undifferentiated, highly proliferative, metastatic
tumors with a high incidence of spontaneous regression,
affecting young infants. Accurate distinction of
spontaneously regressing infant NB from high risk infant
stage 4 can be difficult, but critical for therapeutic deci-
sions. In our hands, the intensely positive CHD5 nuclear
staining enabled a clear distinction of stage 4s NB from
stage 4 NB, which was consistently immunonegative.
These results are consistent with our previous gene
expression profiling study, where similar differential
CHD5 expression profiles were observed amongst
infants with disseminated NB subgroups [18]. Thus,
CHD5 immunohistochemical staining may be clinically
useful for a more accurate characterization of dissemi-
nated infant NB.
In NB, CHD5 nuclear staining was strongly asso-
ciated with established favorable prognostic variables
Figure 4 Chemotherapy-induced expression of CHD5 in 12 high risk NB tumors. (A) CHD5 immunoreactivity pre- and post-chemotherapy
(400x); (B) Kaplan-Meier analysis for OS was performed using the mean between pre-treatment and post-treatment gene expression levels as
cut-off to divide tumors which reactivate CHD5 and tumors that maintain low expression levels; (C) CHD5 transcript levels quantified by qRT-PCR:
CHD5 expression levels (Black) at diagnosis, (Grey) post-chemotherapy. Fetal brain CHD5 expression represents normal neural tissue values.
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Page 11 of 14like low clinical stage, age at diagnosis <12 months and
favorable histology. Our findings suggest that CHD5
protein expression may accurately define NB risk
groups and may, therefore, be a prognostic marker.
Evidence is provided by the statistically significant
association found between high CHD5 immunoreactiv-
i t ya n df a v o r a b l eO Sa n dE F S .T h e s er e s u l t sa r ec o n s i s -
tent with recent studies reporting a strong association
of CHD5 mRNA levels with patient outcome in NB
[5,10]. Furthermore, Cox multivariate analyses suggest
that the prognostic value of CHD5 protein expression
is independent of other clinical and biological variables
currently used in risk stratification of NB patients and
could therefore represent an immunohistochemical
marker of prognosis in NB.
Currently, risk stratification of NB patients is per-
formed by combining different markers with strong
prognostic impact, including patients’ age at diagnosis,
tumor stage, genomic amplification of the oncogene
MYCN, copy number alterations of chromosomal
regions 1p, 11q and 17q, tumor DNA content [1,19] and
Shimada histological score [20]. However, despite elabo-
rate risk stratification strategies, outcome prediction in
neuroblastoma is still deficient. In recent years, to
improve risk assessment additional prognostic indicators
such as gene-expression signatures [21-23], combined
genomic and molecular signatures [24] or expression
levels of single candidate genes, e.g., Trk (NTRK) family
of neurotrophin receptors [25,26], FYN [27], PRAME
[28] and ZNF423 [29], have been associated with NB
clinical behavior. Expression of the Trk family receptors
has been the most extensively characterized marker in
NB and has been found to be consistently correlated
with the biology and clinical behavior of NB. Based on
our results, there is an apparent similarity between the
expression patterns of CHD5 and TRKA in NB and their
patterns of association with NB disease outcome. TRKA
expression has been reported to be high in biologically
favorable NB tumors and inversely associated with
MYCN amplification [30]. The prognostic value of the
immunohistochemical detection of TrkA has also been
examined and reported to be high, especially in combi-
nation with Ha-Ras expression pattern [31,32]. Further
IHC studies have correlated the lack of TrkA expression
with metastatic malignant NB [33]. However, in the lat-
ter study, 34% of the patients with stage 4 NB displayed
TrkA expression, a subset of which died of aggressive
metastatic disease despite TrkA expression [33,34]. In
our study, the majority of stage 4 NB either lacked
CHD5 immunoreactivity (83%) or exhibited weak
nuclear staining (13%), a high risk phenotype according
to our scoring system. Only one stage 4 tumor was
found to be clearly immunoreactive for CHD5; at the
time of analysis the patient is alive, 29 months from
diagnosis. These observations further confirm CHD5 as
a powerful prognostic marker that could complement
other known markers such as age at diagnosis, stage,
MYCN status, cellular DNA content, 1p deletion and
tumor histology. However, the potential clinical use of
this marker must be tested in larger, prospective
cohorts.
It is known that tumor histology and gene expression can
change with treatment as a result of important changes in
cellular processes, e.g., induced tumor differentiation, DNA
repair, apoptosis and tissue necrosis. Undifferentiated NB
occasionally exhibit neuroblastic maturation in response to
chemotherapy. Assessment of CHD5 gene and protein
expression in NB post-therapy specimens revealed that
tumors with evident neuroblastic maturation showed both
CHD5 gene and protein reactivation. Notably, none of
these tumors harbored 1p deletion. Conversely, in tumors
where minimal or no morphological changes were
observed in the post-treatment specimens, low CHD5
expression persisted. These observations suggest the exis-
tence of a subset of tumors within high risk NB where
CHD5 expression can be reactivated from the silenced
state by standard chemotherapy. Remarkably, when post-
therapy reactivation was observed, CHD5 expression was
largely associated with disease response to cytotoxic induc-
tion therapy and subsequently with longer patient OS. All
12 patients included in the study received the same treat-
ment, nevertheless some tumors failed to respond. At pre-
sent, treatment response in NB is routinely evaluated by
monitoring urine levels of catecholamine and its metabo-
lites (VMA/HVA ratio) and by estimating the decrease in
the size of measurable lesions with conventional imaging
modalities, such as computed tomography (CT) or mag-
netic resonance imaging (MRI). At the time of second-look
surgery, the degree of induced tumor cell differentiation
and the extent of necrosis can also be useful to estimate
treatment response. However, no biological markers for
tumor chemotherapy responsiveness have been reported in
NB. The use of such biomarkers would make chemother-
apy more effective for individual patients by allowing
timely changes of therapy in the case of nonresponding
tumors. Furthermore, markers reflecting tumor response
can function as surrogates of long-term outcome. Taking
into account the small cohort of cases that may have led to
an overestimation of the data, our findings would suggest
that restoration of CHD5 expression could be a surrogate
marker of treatment response that can be clinically useful
to identify patients that do not benefit from conventional
treatment. These results warrant further investigation in a
larger cohort of uniformly treated patients.
In summary, we report that the differential expression
of the neuron-specific protein CHD5 accurately defines
NB risk groups and may represent a marker of outcome
in neuroblastoma that can be tested by conventional
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Page 12 of 14immunohistochemistry. In high risk NB patients, re-
establishment of CHD5 expression following chemother-
apy should be tested prospectively as a surrogate marker
of treatment response.
Additional material
Additonal file 1: Clinical and biological characteristics of 90 NT
specimens included in the study. INSS = International Neuroblastoma
Staging System; Diagnosis: NB = neuroblastoma, GNB =
ganglioneuroblastoma, GN = ganglioneuroma; Disease status: A = alive,
D = dead; EFS = Event free survival; qRT-PCR = Quantitative real-time
PCR; IHC = immunohistochemistry; n.a = not available data
Immunohistochemical analysis of CHD5 expression in NTs Results
are displayed as percentage of CHD5 immunopositive cells present in
each tumor specimen. Staining intensity: 0 = negative; 1 = weak staining;
2 = strong staining, 3 = very intense staining. Proportion of positive cells
values (<25% = 1; 25-75 = 2; >75% = 3). Intensity and positive cell values
were multiplied together to provide a single score for each case.
Additonal file 2: A. Immunohistochemical staining of FFPE sections
of two immunopositive neuroblastic tumors using two different
batches of the anti-CHD5 antibody (T00251-A1 and T00251-A02); B.
Immunochemical assay with the anti-CHD5 antibody (Strategic
Diagnostics, DE) on mouse xenografts derived from human NB cell
lines. The specificity of the anti-CHD5 antibody was validated by
immunohistochemical assays on FFPE sections of mouse xenografts of
human NB cell lines (SK-N-JD, SK-N-LP and SK-N-AS). In these NB cell
lines CHD5 gene expression is very low or absent (data not shown),
similar to previously reported data (ref. 5, ref. 10). Two different anti-
CHD5 antibody batches (T00251-A1 and T00251-A02, Strategic
Diagnostics, DE) were tested. Ganglioneuroblastoma FFPE tissue sections
were used as positive control samples. All the analyzed xenographs were
composed nearly exclusively (>95%) of neuroblastic cells exhibiting no
CHD5 nuclear staining and faint cytoplasmic staining (when present).
Only few (<5%) immunopositve cells were observed in the SK-N-LP
xenograft. However, viable tumor cells in the SK-N-LP xenograft where
negative for CHD5 nuclear staining, similar to SK-N-JD and SK-N-AS.
These results were comparable to the immunostaining pattern observed
in undifferentiated high risk NB tumors. The GNB ganglionar cells
showed intense nuclear and diffused cytoplasm immunostaining.
Additional file 3: CHD5 mRNA expression levels in NTs Results are
displayed as mean expression levels of NT subgroups obtained from two
independent analyses. HR = high risk NB (Stage 4 and Stage 3 MYCN
amplified); LR = low risk NB (stage 1, stage 2 and stage 3 MYCN non-
amplified); GNB= ganglioneuroblastoma; GN = ganglioneuroma.
Quantification was performed relative to normal fetal brain. Error bars
illustrate the variability amongst the samples of each NT subgroup.
Additional file 4: Comparison of CHD5 mRNA and protein
expression. The lineal graph shows comparison between CHD5 mRNA
levels and protein immunoreactivity in 34 NB cases. Low CHD5 protein
scores were associated with lower mRNA levels (negative z-score values),
and high IHC scores with high mRNA expression (positive z-score values),
(Spearman’s correlation analysis rho = 0.774; P < 0.001). Low risk tumors,
stage 4s and infant stage 1 NB tumors showed very intense nuclear
staining in comparison to the observed transcript levels (cases # 1-6, 30,
31 and 33).
Additional file 5: Cox multivariate análisis. Cox multivariate regression
analysis has been performed using clinical and biological variables
currently used in risk stratification of NB patients (INSS stage, age at
diagnosis, MYCN status and 1p LOH) in combination with the CHD5 IHC.
The analysis has been performed sequentially, adding one variable at
each step, in order to assess how the presence of each variable
influences the performance of CHD5. CHD5 IHC remained statistically
significantly associated with overall survival in all the analyses, except
when the 1p LOH parameter is included in the overall survival analysis.
This is due to the strong association of the expression of CHD5, located
on 1p36, with chromosome 1p status. All the rest of variables, except for
MYCN amplification, were not statistically significant. For event free
survival analysis, CHD5 IHC is the only variable that remained statistically
significant along the whole analysis, even in the presence of 1p LOH. IHC
= Immunohistochemical analysis; INSS = International Neuroblastoma
Staging System; HR = hazard ratio; CI = confidence interval. P-values are
two sided.
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